Elucidata, a Cambridge, MA-based TechBio company that powers life science research & development (R&D), raised $16M in Series A funding.
The round was led by Eight Roads Ventures, with participation from F-Prime Capital, IvyCap Ventures, and Hyperplane Venture Capital.
The company intends to use the funds to deepen product capabilities in translational drug research and allied markets, scale go-to-market initiatives, and accelerate global expansion of operations.
Founded in 2015 by University of Chicago and MIT graduate Dr. Abhishek Jha and IIT Delhi alumnus Swetabh Pathak, Elucidata powers life science research & development (R&D) with its data-centric Machine Learning Operations (ML-Ops) platform. Polly provides R&D teams access to clean, curated biomolecular data that can be queried and analyzed over a graphical user interface (GUI) or programmatically. It leverages proprietary Bio-NLP technology to rapidly curate biomedical data with human-levels of accuracy, making it machine learning-ready (ML-ready).
Today, 30+ premier life science companies, including Genentech, Pfizer, Janssen as well as research institutes like Stanford and Bill & Melinda Gates Foundation are using Polly to shorten their drug discovery cycles.
FinSMEs
27/09/2022